Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Tuesday.

According to Zacks, “Dova Pharmaceuticals, Inc. is a pharmaceutical company. It focuses on acquiring, developing and commercializing drug candidates for thrombocytopenia diseases. The company’s drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist which are in clinical stage. Dova Pharmaceuticals, Inc. is based in Durham, North Carolina. “

Other research analysts have also issued research reports about the stock. Leerink Swann assumed coverage on shares of Dova Pharmaceuticals in a research report on Monday, July 24th. They set a “market perform” rating and a $24.00 target price on the stock. J P Morgan Chase & Co initiated coverage on shares of Dova Pharmaceuticals in a report on Monday, July 24th. They set an “overweight” rating and a $35.00 price target for the company. Finally, Jefferies Group LLC initiated coverage on shares of Dova Pharmaceuticals in a report on Monday, July 24th. They set a “buy” rating and a $30.00 price target for the company.

Shares of Dova Pharmaceuticals (DOVA) traded up $1.79 on Tuesday, reaching $24.92. 38,500 shares of the company were exchanged, compared to its average volume of 125,397. Dova Pharmaceuticals has a twelve month low of $16.98 and a twelve month high of $29.99.

Dova Pharmaceuticals (NASDAQ:DOVA) last announced its quarterly earnings results on Thursday, November 9th. The company reported ($0.38) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.08). During the same quarter last year, the business posted ($0.41) EPS. equities analysts forecast that Dova Pharmaceuticals will post -1.4 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Dova Pharmaceuticals, Inc. (DOVA) Cut to Hold at Zacks Investment Research” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this story on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/11/14/dova-pharmaceuticals-inc-dova-cut-to-hold-at-zacks-investment-research.html.

In related news, Director Paul B. Manning acquired 25,870 shares of the company’s stock in a transaction that occurred on Wednesday, August 16th. The stock was acquired at an average price of $22.30 per share, with a total value of $576,901.00. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink.

Several hedge funds have recently added to or reduced their stakes in the company. Perceptive Advisors LLC raised its stake in shares of Dova Pharmaceuticals by 2.8% during the third quarter. Perceptive Advisors LLC now owns 1,754,015 shares of the company’s stock valued at $42,587,000 after acquiring an additional 47,516 shares during the last quarter. Fosun International Ltd raised its stake in shares of Dova Pharmaceuticals by 9.2% during the third quarter. Fosun International Ltd now owns 710,000 shares of the company’s stock valued at $17,239,000 after acquiring an additional 60,000 shares during the last quarter. California State Teachers Retirement System bought a new position in shares of Dova Pharmaceuticals during the third quarter valued at $202,000. Pier Capital LLC raised its stake in shares of Dova Pharmaceuticals by 118.5% during the third quarter. Pier Capital LLC now owns 116,715 shares of the company’s stock valued at $2,834,000 after acquiring an additional 63,289 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. bought a new position in shares of Dova Pharmaceuticals during the third quarter valued at $241,000. 23.67% of the stock is owned by hedge funds and other institutional investors.

Dova Pharmaceuticals Company Profile

Dova Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD).

Get a free copy of the Zacks research report on Dova Pharmaceuticals (DOVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Dova Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.